- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03859063
Long-term Follow-up After Stroke (The LAST-long Trial) (LAST-long)
A Multimodal Individualized Intervention to Prevent Functional Decline After Stroke. A Randomized Controlled Trial on Long-term Follow-up After Stroke (The LAST-long Trial)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In a clinical randomized controlled trial, participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months.
The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
Those randomized to the control group will receive standard care.
Patients living in the municipalities of Trondheim, Lørenskog and Skedsmo admitted to Akershus University Hospital or St. Olavs University Hospital will be included at the outpatients clinic 3 months after the stroke.
All patients will be re-assessed at 6, 12 and 18 months after inclusion. Primary outcome will be modified Rankin Scale at 18 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Torunn Askim, phd prof
- Phone Number: +47 73412556
- Email: torunn.askim@ntnu.no
Study Locations
-
-
-
Lørenskog, Norway
- Recruiting
- Akershus University Hospital
-
Contact:
- Bente Thommessen, PhD
- Email: Bente.Thommessen@ahus.no
-
Contact:
- Elin Bergh, MD
- Email: Elin.Josefina.Bergh@ahus.no
-
Sandvika, Norway
- Recruiting
- Vestre Viken Bærum Hospital
-
Contact:
- Håkon Hile-Hansen
- Email: HAAIHL@vestreviken.no
-
Trondheim, Norway
- Recruiting
- St Olavs Hospital Stroke Unit
-
Contact:
- Torunn Askim, phd prof
- Email: torunn.askim@ntnu.no
-
Contact:
- Anne Hokstad, phd
- Email: anne.hokstad@ntnu.no
-
Ålesund, Norway, 6017
- Recruiting
- Alesund Hospital
-
Contact:
- Møre and Romsdal H Trust
-
Contact:
- Yngve M Seljeseth
- Email: Yngve.Muller.Seljeseth@helse-mr.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of first ever or recurrent stroke (ischemic stroke or hemorrhage)
- mRS < 5
- Living in Trondheim, Skedsmo or Lørenskog municipality
- Less than 10 points on Short Physical Performance Battery (SPPB) OR less than 26 points on Montreal Cognitive Assessment (MoCA) OR more than 27 points on the 7 item version of the Fatigue Severity Scale (FSS-7) OR more than 7 points on the depression or anxiety items on Hospital Anxiety and Depression Scale (HADS) OR reduced hand function (i.e. fails on Motor Assessment Scale - Advanced arm- and hand function, item 3)
- Able to understand Norwegian
- Able and willing to sign informed consent.
Exclusion Criteria:
- Life expectancy < 12 months
- Other serious diseases, judged by the medical doctor to make it difficult to comply with the intervention (i.e. serious neurological diseases or drug abuse).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Regular follow up by a community based stroke coordinator
|
Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months.
The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
|
Active Comparator: Control
Usual care
|
Community based follow-up as usual
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Rankin Scale (mRS)
Time Frame: 18 months
|
mRS is an ordinal scale ranging from 0 to 6 measuring global function.
0 denotes no symptoms while 6 denotes death.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Rankin Scale (mRS)
Time Frame: 6 months
|
mRS is an ordinal scale ranging from 0 to 6 measuring global function.
0 denotes no symptoms while 6 denotes death.
|
6 months
|
Modified Rankin Scale (mRS)
Time Frame: 12 months
|
mRS is an ordinal scale ranging from 0 to 6 measuring global function.
0 denotes no symptoms while 6 denotes death.
|
12 months
|
Barthel Index
Time Frame: 6 months
|
ADL function
|
6 months
|
Barthel Index
Time Frame: 12 months
|
ADL function
|
12 months
|
Barthel Index
Time Frame: 18 months
|
ADL function
|
18 months
|
Nottingham IADL
Time Frame: 6 months
|
Extended activities of daily life (ADL) function
|
6 months
|
Nottingham IADL
Time Frame: 12 months
|
Extended activities of daily life (ADL) function
|
12 months
|
Nottingham IADL
Time Frame: 18 months
|
Extended activities of daily life (ADL) function
|
18 months
|
Stroke Impact Scale (SIS)
Time Frame: 6 months
|
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains.
The scale within each domain range from 0 to 100 and higher score denotes better health.
|
6 months
|
Stroke Impact Scale (SIS)
Time Frame: 12 months
|
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains.
The scale within each domain range from 0 to 100 and higher score denotes better health.
|
12 months
|
Stroke Impact Scale (SIS)
Time Frame: 18 months
|
SIS is a stroke specific quality of life measure, that measures self perceived health within nine domains.
The scale within each domain range from 0 to 100 and higher score denotes better health.
|
18 months
|
The 5-level EQ-5D version (EQ-5D-5L)
Time Frame: 6 months
|
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
|
6 months
|
The 5-level EQ-5D version (EQ-5D-5L)
Time Frame: 12 months
|
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
|
12 months
|
The 5-level EQ-5D version (EQ-5D-5L)
Time Frame: 18 months
|
EQ-5D-5L is a generic quality of life measure reporting self perceived health within five domains.
|
18 months
|
Short Physical Performance Battery (SPPB)
Time Frame: 6 months
|
SPPB is a composite scale measuring gait and balance.
The scale ranges from 0 to 12 points.
Higher score denotes better function.
|
6 months
|
Short Physical Performance Battery (SPPB)
Time Frame: 12 months
|
SPPB is a composite scale measuring gait and balance.
The scale ranges from 0 to 12 points.
Higher score denotes better function.
|
12 months
|
Short Physical Performance Battery
Time Frame: 18 months
|
SPPB is a composite scale measuring gait and balance.
The scale ranges from 0 to 12 points.
Higher score denotes better function.
|
18 months
|
Dynamometer
Time Frame: 6 months
|
Grip strength
|
6 months
|
Dynamometer
Time Frame: 12 months
|
Grip strength
|
12 months
|
Dynamometer
Time Frame: 18 months
|
Grip strength
|
18 months
|
6 Minute Walk Test
Time Frame: 6 months
|
Endurance.
Walking distance during 6 minutes.
|
6 months
|
6 Minute Walk Test
Time Frame: 12 months
|
Endurance.
Walking distance during 6 minutes.
|
12 months
|
6 Minute Walk Test
Time Frame: 18 months
|
Endurance.
Walking distance during 6 minutes.
|
18 months
|
ActivPAL
Time Frame: 6 months
|
Activity monitoring across seven days
|
6 months
|
ActivPAL
Time Frame: 12 months
|
Activity monitoring across seven days
|
12 months
|
ActivPAL
Time Frame: 18 months
|
Activity monitoring across seven days
|
18 months
|
Montreal Cognitive Assessment
Time Frame: 6 months
|
Cognitive function
|
6 months
|
Montreal Cognitive Assessment
Time Frame: 12 months
|
Cognitive function
|
12 months
|
Montreal Cognitive Assessment
Time Frame: 18 months
|
Cognitive function
|
18 months
|
Trail making test A and B
Time Frame: 6 months
|
Executive function
|
6 months
|
Trail making test A and B
Time Frame: 12 months
|
Executive function
|
12 months
|
Trail making test A and B
Time Frame: 18 months
|
Executive function
|
18 months
|
Global Deterioration Scale (GDS)
Time Frame: 6 months
|
GDS is a measure of global cognitive function.
A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
|
6 months
|
Global Deterioration Scale (GDS)
Time Frame: 12 months
|
GDS is a measure of global cognitive function.
A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
|
12 months
|
Global Deterioration Scale (GDS)
Time Frame: 18 months
|
GDS is a measure of global cognitive function.
A score of 1 denotes no symptoms while a score of 7 denotes serious dementia.
|
18 months
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 6 months
|
The HADS is a fourteen item scale that generates ordinal data.
Seven of the items relate to anxiety and seven relate to depression.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
|
6 months
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 12 months
|
The HADS is a fourteen item scale that generates ordinal data.
Seven of the items relate to anxiety and seven relate to depression.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
|
12 months
|
Hospital Anxiety and Depression Scale (HADS)
Time Frame: 18 months
|
The HADS is a fourteen item scale that generates ordinal data.
Seven of the items relate to anxiety and seven relate to depression.
Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
|
18 months
|
Fatigue Severity Scale (FSS-7)
Time Frame: 6 months
|
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue.
FSS-7 contains seven statements that rate the severity of fatigue.
Each item is scored from 1 to 7. Higher score is indicating more fatigue.
|
6 months
|
Fatigue Severity Scale (FSS-7)
Time Frame: 12 months
|
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue.
FSS-7 contains seven statements that rate the severity of fatigue.
Each item is scored from 1 to 7. Higher score is indicating more fatigue.
|
12 months
|
Fatigue Severity Scale (FSS-7)
Time Frame: 18 months
|
The seven item version of Fatigue Severity Scale is a method of evaluating the impact of fatigue.
FSS-7 contains seven statements that rate the severity of fatigue.
Each item is scored from 1 to 7. Higher score is indicating more fatigue.
|
18 months
|
Part 2 of the Client Service Receipt Inventory
Time Frame: 6 months
|
A measure of caregivers work participation and absenteeism
|
6 months
|
Part 2 of the Client Service Receipt Inventory
Time Frame: 12 months
|
A measure of caregivers work participation and absenteeism
|
12 months
|
Part 2 of the Client Service Receipt Inventory
Time Frame: 18 months
|
A measure of caregivers work participation and absenteeism
|
18 months
|
Total cholesterol
Time Frame: 6 months
|
The level of total cholesterol will be measured by a blood test
|
6 months
|
Total cholesterol
Time Frame: 12 months
|
The level of total cholesterol will be measured by a blood test
|
12 months
|
Total cholesterol
Time Frame: 18 months
|
The level of total cholesterol will be measured by a blood test
|
18 months
|
Low Density Lipoprotein (LDL)
Time Frame: 6 months
|
The LDL level will be measured by a blood test
|
6 months
|
Low Density Lipoprotein (LDL)
Time Frame: 12 months
|
The LDL level will be measured by a blood test
|
12 months
|
Low Density Lipoprotein (LDL)
Time Frame: 18 months
|
The LDL level will be measured by a blood test
|
18 months
|
High Density Lipoprotein (HDL)
Time Frame: 6 months
|
The HDL level will be measured by a blood test
|
6 months
|
High Density Lipoprotein (HDL)
Time Frame: 12 months
|
The HDL level will be measured by a blood test
|
12 months
|
High Density Lipoprotein (HDL)
Time Frame: 18 months
|
The HDL level will be measured by a blood test
|
18 months
|
Longterm blood sugar (HbA1c)
Time Frame: 6 months
|
The HbA1c level will be measured by a blood test
|
6 months
|
Longterm blood sugar (HbA1c)
Time Frame: 12 months
|
The HbA1c level will be measured by a blood test
|
12 months
|
Longterm blood sugar (HbA1c)
Time Frame: 18 months
|
The HbA1c level will be measured by a blood test
|
18 months
|
Hemoglobin
Time Frame: 6 months
|
The hemoglobin level will be measured by a blood test
|
6 months
|
Hemoglobin
Time Frame: 12 months
|
The hemoglobin level will be measured by a blood test
|
12 months
|
Hemoglobin
Time Frame: 18 months
|
The hemoglobin level will be measured by a blood test
|
18 months
|
Creatinine
Time Frame: 6 months
|
The creatinine level will be measured by a blood test
|
6 months
|
Creatinine
Time Frame: 12 months
|
The creatinine level will be measured by a blood test
|
12 months
|
Creatinine
Time Frame: 18 months
|
The creatinine level will be measured by a blood test
|
18 months
|
C-reactive protein (CRP)
Time Frame: 6 months
|
The CRP level will be measured by a blood test
|
6 months
|
C-reactive protein (CRP)
Time Frame: 12 months
|
The CRP level will be measured by a blood test
|
12 months
|
C-reactive protein (CRP)
Time Frame: 18 months
|
The CRP level will be measured by a blood test
|
18 months
|
Blood pressure
Time Frame: 6 months
|
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
|
6 months
|
Blood pressure
Time Frame: 12 months
|
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
|
12 months
|
Blood pressure
Time Frame: 18 months
|
Systolic and diastolic blood pressure will be measured by use of a sphygmomanometer
|
18 months
|
Body mass index (BMI)
Time Frame: 6 months
|
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
|
6 months
|
Body mass index (BMI)
Time Frame: 12 months
|
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
|
12 months
|
Body mass index (BMI)
Time Frame: 18 months
|
BMI calculated as kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared
|
18 months
|
Health care costs
Time Frame: 18 months
|
Data from available registries will be used to estimate costs in Euro
|
18 months
|
Adherence to the intervention
Time Frame: 18 months
|
Number of attended meetings with the stroke coordinator
|
18 months
|
Exercise Adherence Rating Scale
Time Frame: 18 months
|
Exercise Adherence Rating Scale measures the level of adherence to the recommended and agreed activities and the reasons for not adhering.
|
18 months
|
Patient diaries
Time Frame: 18 months
|
Adherence to the recommended and agreed activities
|
18 months
|
Adverse events
Time Frame: 18 months
|
Adverse events will be registered to assess the safety of the intervention.
|
18 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Jorunn Helbostad, phd prof, Norwegian University for Science and Technology
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018/1809
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on Intervention
-
Biolux Research Holdings, Inc.TerminatedOrthodontic Tooth MovementCanada
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedColorectal Carcinoma | Healthy Subject | Health Status UnknownUnited States
-
University of FloridaCompletedSensitivityUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Institute on Minority Health and...RecruitingHuman Papillomavirus InfectionUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnCancer Survivor | Peripheral Sensory Neuropathy
-
Nottingham Trent UniversityUnknownOverweight and ObesityUnited Kingdom
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...American Cancer Society, Inc.Completed
-
Vanderbilt UniversityAgency for Healthcare Research and Quality (AHRQ)Completed